Correlation Between MDxHealth and LumiraDx
Can any of the company-specific risk be diversified away by investing in both MDxHealth and LumiraDx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining MDxHealth and LumiraDx into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between MDxHealth SA ADR and LumiraDx, you can compare the effects of market volatilities on MDxHealth and LumiraDx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in MDxHealth with a short position of LumiraDx. Check out your portfolio center. Please also check ongoing floating volatility patterns of MDxHealth and LumiraDx.
Diversification Opportunities for MDxHealth and LumiraDx
Pay attention - limited upside
The 3 months correlation between MDxHealth and LumiraDx is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding MDxHealth SA ADR and LumiraDx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on LumiraDx and MDxHealth is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on MDxHealth SA ADR are associated (or correlated) with LumiraDx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of LumiraDx has no effect on the direction of MDxHealth i.e., MDxHealth and LumiraDx go up and down completely randomly.
Pair Corralation between MDxHealth and LumiraDx
If you would invest (100.00) in LumiraDx on November 28, 2024 and sell it today you would earn a total of 100.00 from holding LumiraDx or generate -100.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Flat |
Strength | Insignificant |
Accuracy | 0.0% |
Values | Daily Returns |
MDxHealth SA ADR vs. LumiraDx
Performance |
Timeline |
MDxHealth SA ADR |
LumiraDx |
Risk-Adjusted Performance
Very Weak
Weak | Strong |
MDxHealth and LumiraDx Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with MDxHealth and LumiraDx
The main advantage of trading using opposite MDxHealth and LumiraDx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if MDxHealth position performs unexpectedly, LumiraDx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in LumiraDx will offset losses from the drop in LumiraDx's long position.MDxHealth vs. Inozyme Pharma | MDxHealth vs. Day One Biopharmaceuticals | MDxHealth vs. Acumen Pharmaceuticals | MDxHealth vs. Eledon Pharmaceuticals |
LumiraDx vs. Fonar | LumiraDx vs. Burning Rock Biotech | LumiraDx vs. Sera Prognostics | LumiraDx vs. Exagen Inc |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Complementary Tools
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |